Healthcare communication company Conversa Health revealed on Tuesday that it has appointed a new chief technology officer, Cameron Ough.
In his new role, Ough is expected to be a key leader in the continued development and implementation of a comprehensive business strategy to address opportunities in the Provider, Payer and Pharma markets. The company said Ough will establish and grow its technology roadmap and lead all the technical initiatives, focusing on customer/end-user satisfaction and value metrics for clients and partners.
Ough previously worked at Cigna for ten years, where he served as a senior director in IT, with responsibility for Clinical Data Interoperability and Consumer & Digital Health.
Earlier, Ough spent ten years at Intel in several technology initiatives as an engineering and architecture lead. He reportedly pioneered projects that included data centre management capabilities, product and service localisation. He was also the solution lead for Intel Digital Health's Remote Care Management platform.
Conversa is an intelligent, automated conversation platform for healthcare. The company has an extensive library of over 700+ clinically-intelligent conversation programs that include asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension, and joint replacement. With its innovative and scalable Conversational AI technology, Conversa said healthcare organizations can deliver automated, personalized doctor-patient conversation experiences that lead to more meaningful patient relationships, effective population management and, ultimately, better clinical and financial outcomes.
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees